Tirzepatide / Mounjaro Research Overview

Tirzepatide / Mounjaro Research Overview

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors and the active substance in authorised medicinal products (sold under brand names including Mounjaro). VQ Health supplies tirzepatide reference material strictly for in-vitro laboratory research — this article is scientific education, not patient information.

Authorised medicine vs research discussion

Authorised products undergo regulatory review of manufacturing, quality and clinical data and are prescribed under medical supervision. Research reference compounds are a separate category: they are laboratory materials, not medicines, and are not for human or veterinary use.

The research background

Tirzepatide was evaluated across the SURPASS (glycaemic research) and SURMOUNT (weight research) phase 3 programmes — among the largest datasets in incretin science. Receptor-pharmacology work (Willard et al., 2020) showed the molecule is an 'imbalanced' agonist, engaging GIP receptors more potently than GLP-1 receptors in vitro.

Mechanistic comparisons

Versus single GLP-1 agonists, dual agonism is studied for additive or complementary signalling. Versus triple agonists (retatrutide), tirzepatide lacks glucagon-receptor engagement — the key structural difference in current comparative research.

References

• Jastreboff AM et al. N Engl J Med 2022;387:205-216.
• Frias JP et al. N Engl J Med 2021;385:503-515.
• Willard FS et al. JCI Insight 2020;5:e140532.

Educational content only. No dosing, administration or treatment guidance is provided.